Comparative analysis of immunotherapy responses in small cell lung cancer patients with dermatomyositis
When considering the use of immune checkpoint inhibitors in Small Cell Lung Cancer (SCLC) with accompanying Dermatomyositis (DM), it's essential to evaluate the anticancer effect, the risk of immune-related adverse effects (irAEs), and the potential for worsening of DM. Additionally, factors such as the patient's overweight status, the severity of the initial skin lesions, and the Lactate Dehydrogenase (LDH) levels should be taken into account. AbstractCancer-associated dermatomyositis (CAD), a paraneoplastic syndrome characterized by dermatomyositis (DM), frequently presents in association with small cell lung cancer (SCL...
Source: Thoracic Cancer - February 14, 2024 Category: Cancer & Oncology Authors: So ‐yun Kim,
Duk Ki Kim,
Song‐Yi Choi,
Chaeuk Chung Tags: CASE REPORT Source Type: research
Anti-MDA5 Antibody-positive Clinically Amyopathic Dermatomyositis with Rapidly Progressing Interstitial Lung Disease Successfully Treated by Initiation of Combined Immunosuppressive Therapy Plus Plasma Exchange and Subsequently Switching Tacrolimus to Tofacitinib
Intern Med. 2024 Feb 12. doi: 10.2169/internalmedicine.2915-23. Online ahead of print.ABSTRACTA 36-year-old man with inverse Gottron's sign was admitted for clinically amyopathic dermatomyositis (CADM) with rapidly progressive interstitial lung disease (RP-ILD). Early addition of plasma exchange (PE) to triple therapy improved severe respiratory failure and transiently decreased serum ferritin levels and anti-melanoma differentiation-associated gene 5 antibody (anti-MDA5 Ab) titers. Furthermore, switching from tacrolimus to tofacitinib resulted in disease remission. Recognition of the inverse Gottron's sign may allow for t...
Source: Internal Medicine - February 12, 2024 Category: Internal Medicine Authors: Masami Yamazoe Kazuya Takeda Yutaro Nagano Kanami Nagano Koji Kato Takashi Inoue Kazuhiro Horiuchi Kazuro Kamada Source Type: research
Small cell lung cancer with dermatomyositis: a case report
In conclusion, we present a comprehensive case study of dermatomyositis as a paraneoplastic syndrome throughout the treatment process. The response to tumor therapy coincided with the amelioration of dermatomyositis symptoms. Therefore, diligent malignancy screening is imperative for patients diagnosed with dermatomyositis. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - February 12, 2024 Category: Cancer & Oncology Source Type: research
ACR Image Competition 2023 Results, Part 3
For the 2023 Image Competition, the ACR sought images representing a diverse range of patients with idiopathic inflammatory myopathies (IIMs) or IIM mimics. Chronic Facial Ulcers in Anti-Melanoma-Differentiation-Associated Gene 5 (MDA-5) Antibody Amyopathic Dermatomyositis These images depict a 27-year-old patient who developed erythematous violaceous lesions over his upper chest, face and scalp over six months.... (Source: The Rheumatologist)
Source: The Rheumatologist - February 9, 2024 Category: Rheumatology Authors: Rajat Ranka, MD Tags: Conditions Myositis amyopathic dermatomyositis image case report Image Competition Source Type: research
Clinically amyopathic dermatomyositis associated with cutaneous ulcerations: a case-based review
CONCLUSION: The authors presented a case of seronegative CADM featuring skin vasculopathy, successfully treated with consecutive methylprednisolone pulses. Our literature review emphasized the importance of focused CADM management trials, highlighting the need for further research.PMID:38333314 | PMC:PMC10849458 | DOI:10.1097/MS9.0000000000001669 (Source: Annals of Medicine)
Source: Annals of Medicine - February 9, 2024 Category: Internal Medicine Authors: Alice Viana De Jesus Jean Marcos De Souza Source Type: research
Targeted antibodies and tumor microenvironment dynamics in dermatomyositis: Shared therapeutic approaches
(Source: International Journal of Rheumatic Diseases)
Source: International Journal of Rheumatic Diseases - February 8, 2024 Category: Rheumatology Authors: Po ‐Hung Chen,
Meng‐Yu Wu,
Wan‐Ting Liao,
Su‐Boon Yong,
Chia‐Jung Li,
I‐Ming Jou Tags: LETTER TO THE EDITOR Source Type: research
Mitochondrial-related hub genes in dermatomyositis: muscle and skin datasets-based identification and in vivo validation
Conclusion: The mito-hub genes (IFI27, CMPK2, and LAP3) are identified in both muscles and skin tissues from DM patients. These genes may be associated with immune infiltration in DM, providing a new entry point for the pathogenesis of DM. (Source: Frontiers in Genetics)
Source: Frontiers in Genetics - February 8, 2024 Category: Genetics & Stem Cells Source Type: research
Clinical characteristics and symptom progression of dermatomyositis subtypes: a retrospective analysis of a prospective database
Disease characteristics of classic dermatomyositis (DM) and clinically amyopathic DM (CADM) are well-established, but there exists limited knowledge on disease progression of these subtypes. (Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - February 8, 2024 Category: Dermatology Authors: Rachita Pandya, Julianne Kleitsch, Darosa Lim, Victoria P. Werth Source Type: research
Prognostic Role of Interferon ‐λ3 in Anti–Melanoma Differentiation–Associated Gene 5–Positive Dermatomyositis‐Associated Interstitial Lung Disease
ConclusionSerum IFN λ3 is a promising biomarker for identifying patients at high risk of poor outcomes in anti-MDA5 antibody–positive DM-ILD. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - February 7, 2024 Category: Rheumatology Authors: Atsuki Fukada,
Tomoyuki Fujisawa,
Hironao Hozumi,
Keigo Koda,
Taisuke Akamatsu,
Yoshiyuki Oyama,
Yasuomi Satake,
Mitsuru Niwa,
Yusuke Kaida,
Hiroyuki Matsuda,
Koshi Yokomura,
Naoki Koshimizu,
Mikio Toyoshima,
Shiro Imokawa,
Dai Hashimoto,
A Tags: Full Length Source Type: research
Clinical and immunological characteristics and prognosis of patients with autoantibody negative dermatomyositis: a case control study
ConclusionsCompared with MSAs-positive group, MSAs-negative DM patients suffered less from organ involvement compared with MSAs-positive group and tend to have better prognosis.Key PointsMSAs-negative DM patients exhibited distinct characteristics in comparison with MSAs-positive DM patients: •The MSAs ( −)/MAAs (+) DM patients demonstrated a higher prevalence of organizing pneumonia (OP) and usual interstitial pneumonia (UIP), and elevated eosinophil counts in bronchoalveolar lavage fluid. •CEA levels were lower in MSAs-negative patients compared with MSAs-positive patients. •Elevated counts of lymphoc...
Source: Clinical Rheumatology - February 7, 2024 Category: Rheumatology Source Type: research
